For the six months ended 30 June 2025, total revenue was RMB 48.693 million, compared to RMB 48.830 million in the same period of 2024. Revenue from pharmaceutical distribution increased to RMB 43.013 million from RMB 33.267 million, while revenue from pharmaceutical manufacturing decreased to RMB 5.680 million from RMB 15.563 million. Gross profit was RMB 6.212 million, down from RMB 9.527 million in the prior-year period. There was no gain on restructuring of debts in 2025, compared with a gain of RMB 47.356 million in 2024. Other income amounted to RMB 0.692 million in 2025, compared to RMB 0.734 million in 2024. Other losses, net, were RMB 1.623 million, compared to RMB 6.362 million in 2024. Selling and distribution expenses totaled RMB 2.375 million, compared with RMB 3.408 million in the previous period. General and administrative expenses were RMB 5.707 million, down from RMB 7.281 million. Finance costs increased to RMB 6.253 million, compared with RMB 5.075 million in 2024. Depreciation and amortisation was RMB 0.808 million for the period, compared with RMB 1.300 million in the previous period. The consolidated loss before tax for the six months ended 30 June 2025 was RMB 9.054 million, compared to a profit before tax of RMB 35.491 million in the same period of 2024.